Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases

Journal of Thoracic Disease

Volumn 9, Issue 4, 2017, Pages 1144-1154

  Kawamatawong, Theerasuk ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Airway diseases; Roflumilast; Selective phosphodiesterase 4 (PDE4) inhibitor

Indexed keywords

CYCLIC AMP; ROFLUMILAST;

AIRWAY SMOOTH MUSCLE CELL; ASTHMA; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; EOSINOPHIL; HUMAN; INFLAMMATORY CELL; LUNG ALVEOLUS EPITHELIUM CELL; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROBLAST; MAST CELL; NEUTROPHIL; NONHUMAN; RESPIRATORY TRACT DISEASE; REVIEW;

EID: 85018679582     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.21037/jtd.2017.03.116     Document Type: Review

References (99)

1. Francis SH, Corbin JD. Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 1999;36:275-328
2. Grandoch M, Roscioni SS, Schmidt M. The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br J Pharmacol 2010;159:265-84
3. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011;163:53-67
4. Johnson EN, Druey KM. Heterotrimeric G protein signaling: role in asthma and allergic inflammation. J Allergy Clin Immunol 2002;109:592-602
5. Halpin DM. ABCD of the phosphodiesterase family: interaction and differential activity in COPD. Int J Chron Obstruct Pulmon Dis 2008;3:543-61
6. Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 2012;12:275-86
7. Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 2006;117:1237-43
8. Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010;23:235-56
9. Sousa LP, Lopes F, Silva DM, et al. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-?Bindependent manner. J Leukoc Biol 2010;87:895-904
10. Buenestado A, Grassin-Delyle S, Guitard F, et al. Roflumilast inhibits the release of chemokines and TNF-a from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol 2012;165:1877-90
11. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672-88
12. Tenor H, Hatzelmann A, Church MK, et al. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996;118:1727-35
13. Dent G, Giembycz MA, Evans PM, et al. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J Pharmacol Exp Ther 1994;271:1167-74
14. Eskandari N, Wickramasinghe T, Peachell PT. Effects of phosphodiesterase inhibitors on interleukin-4 and interleukin-13 generation from human basophils. Br J Pharmacol 2004;142:1265-72
15. Kung TT, Crawley Y, Luo B, et al. Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines. Br J Pharmacol 2000;130:457-63
16. Hoymann HG, Wollin L, Müller M, et al. Effects of the Phosphodiesterase Type 4 Inhibitor Roflumilast on Early and Late Allergic Response and Airway Hyperresponsiveness in Aspergillus-fumigatus Sensitized Mice. Pharmacology 2009;83:188-95
17. Jones NA, Boswell-Smith V, Lever R, et al. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 2005;18:93-101
18. Sanz MJ, Cortijo J, Taha MA, et al. Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br J Pharmacol 2007;152:481-92
19. Patel BS, Rahman MM, Baehring G, et al. Roflumilast N-oxide in Combination with Formoterol Enhances the Anti-inflammatory Effect of Dexamethasone in ASM Cells. Am J Respir Cell Mol Biol 2017;56:532-8
20. Patel BS, Prabhala P, Oliver BG, et al. Inhibitors of Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase ß2-Agonist-Induced Expression of Antiinflammatory Mitogen-Activated Protein Kinase Phosphatase 1 in Airway Smooth Muscle Cells. Am J Respir Cell Mol Biol 2015; 52:634-40
21. Togo S, Liu X, Wang X, et al. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-ß1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol 2009;296:L959-69
22. Kohyama T, Liu X, Wen F-Q, et al. PDE4 Inhibitors Attenuate Fibroblast Chemotaxis and Contraction of Native Collagen Gels. Am J Respir Cell Mol Biol 2002;26:694-701
23. Cortijo J, Iranzo A, Milara X, et al. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycininduced lung injury. Br J Pharmacol 2009;156:534-44
24. Udalov S, Dumitrascu R, Pullamsetti SS, et al. Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. BMC Pulm Med 2010;10:26
25. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267-79
26. Saetta M, Turato G, Facchini FM, et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997;156:1633-9
27. Takeyama K, Fahy JV, Nadel JA. Relationship of epidermal growth factor receptors to goblet cell production in human bronchi. Am J Respir Crit Care Med 2001;163:511-6
28. Mata M, Sarria B, Buenestado A, et al. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 2005;60:144-52
29. Milara J, Armengot M, Banuls P, et al. Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro. Br J Pharmacol 2012;166:2243-62
30. Liu S, Veilleux A, Zhang L, et al. Dynamic Activation of Cystic Fibrosis Transmembrane Conductance Regulator by Type 3 and Type 4D Phosphodiesterase Inhibitors. J Pharmacol Exp Ther 2005;314:846-54
31. Tannheimer SL, Sorensen EA, Haran AC, et al. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells. Pulm Pharmacol Ther 2012;25:178-84
32. Buenestado A, Chaumais M-C, Grassin-Delyle S, et al. Roflumilast Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-a and Chemokine Production by Human Lung Parenchyma. PLoS ONE 2013;8:e74640
33. Tannheimer SL, Wright CD, Salmon M. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts. Respir Res 2012;13:28
34. Moodley T, Wilson SM, Joshi T, et al. Phosphodiesterase 4 Inhibitors Augment the Ability of Formoterol to Enhance Glucocorticoid-Dependent Gene Transcription in Human Airway Epithelial Cells: A Novel Mechanism for the Clinical Efficacy of Roflumilast in Severe COPD. Mol Pharmacol 2013;83:894-906
35. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365:167-75
36. Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res 2011;12:140
37. van Schalkwyk E, Strydom K, Williams Z, et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005;116:292-8
38. Timmer W, Leclerc V, Birraux G, et al. The New Phosphodiesterase 4 Inhibitor Roflumilast Is Efficacious in Exercise-Induced Asthma and Leads to Suppression of LPS-Stimulated TNF-a Ex Vivo. J Clin Pharmacol 2002;42:297-303
39. Aubier M, Sauer R, Boszormenyi G, et al. Roflumilast a novel selective PDE4 inhibitor shows early onset of efficacy in asthma. Am J Respir Crit Care Med 2004;169:A322 (Abstr)
40. Bousquet J, Aubier M, Sastre J, et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006;61:72-8
41. Leichtl S, Schmid-Wirlitsch C, Bredenbröker D, et al. Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor is effective in the treatment of asthma. Eur Respir J 2002;20:abstr 303S
42. Bateman ED, Goehring U-M, Richard F, Watz H. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-tosevere asthma. J Allergy Clin Immunol 2016;138:142-9.e8
43. Albrecht A, Leichtl S, Bredenbröker D, et al. A new orally active, selective phosphodiesterase 4 inhibitor, with beclomethasone propionate in asthma control. Eur Respir J 2002;20:304S
44. Meltzer EO, Chervinsky P, Busse W, et al. Roflumilast for asthma: Efficacy findings in placebo-controlled studies. Pulm Pharmacol Ther 2015;35:S20-7
45. Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:976-82
46. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007;62:1081-7
47. Global Strategy for Diagnosis, Management, and Prevention of COPD 2014.Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available online: http://www.goldcopd.org/guidelines-global-strategy-fordiagnosis-management.html
48. Nannini LJ, Poole P, Milan SJ, et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;11:CD003794
49. Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001;358:265-70
50. Bredenbröker D, Syed J, Leichtl S, et al. Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease. Eur Respir J 2002;20:abstr 374S
51. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71
52. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94
53. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61
54. Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 2011;12:18
55. Giembycz MA, Field SK. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 2010;4:147-58
56. Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of roflumilast in the chronic obstructive pulmonary disease frequent exacerbator phenotype. Chest 2013;143:1302-11
57. Calverley PM, Martinez FJ, Fabbri LM, et al. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis 2012;7:375-82
58. Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015;385:857-66
59. Martinez FJ, Rabe KF, Sethi S, et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting beta2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Am J Respir Crit Care Med 2016;194:559-67
60. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703
61. Zheng J, Yang J, Zhou X, et al. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study. Chest 2014;145:44-52
62. Welsh EJ, Evans DJ, Fowler SJ, et al. Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2015: CD010337
63. Khoo JK, Venning V, Wong C, et al. Bronchiectasis in the Last Five Years: New Developments. J Clin Med 2016;5:115
64. Park J. Effect Of Roflumilast(Daxas®) In Patients With Symptomatic Non-Cystic Fibrosis Bronchiectasis. Am J Respir Crit Care Med 2014;189: A625
65. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122
66. Martínez-García Má, Soler-Cataluña JJ, Donat Sanz Y, et al. Factors Associated With Bronchiectasis in Patients With COPD. Chest 2011;140:1130-7
67. Martínez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, et al. Prognostic Value of Bronchiectasis in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2013;187:823-31
68. Miravitlles M. Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir Med 2011;105:1118-28
69. Burgel P-R, Nesme-Meyer P, Chanez P, et al. Cough and Sputum Production Are Associated With Frequent Exacerbations and Hospitalizations in COPD Subjects. Chest 2009;135:975-82
70. Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008;31:396-406
71. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016;138:16-27
72. Stockley RA. Neutrophilic inflammation: "Don't you go to pieces on me!" Eur Respir J 2006;28:257-8
73. Zeki AA, Schivo M, Chan A, et al. The Asthma-COPD Overlap Syndrome: A Common Clinical Problem in the Elderly. J Allergy (Cairo) 2011;2011:861926
74. Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol 2013;6:197-219
75. Bateman ED, O'Byrne PM, Buhl R, et al. Roflumilast for asthma: Weighing the evidence. Pulm Pharmacol Ther 2015;35:S1-3
76. Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of Acute Exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 2015;147:894-942
77. Global Strategy for Diagnosis, Management, and Prevention of COP-2016. Available online: http://goldcopd.org/global-strategy-diagnosis-managementprevention-copd-2016/
78. Spina D, Page CP. Xanthines and Phosphodiesterase Inhibitors. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016:1-29
79. Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A 2002;99:8921-6
80. Cosío BG, Shafiek H, Iglesias A, et al. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. Chest 2016;150:123-30
81. Böhmer G, Gleiter CH, Hunnemeyer A, et al. Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults. Int J Clin Pharmacol Ther 2011;49:451-60
82. Oba Y, Lone NA. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis 2013;7:13-24
83. Mills EJ, Druyts E, Ghement I, et al. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol 2011;3:107-29
84. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352:1967-76
85. Ito K, Caramori G, Lim S, et al. Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 2002;166:392-6
86. Milara J, Lluch J, Almudever P, et al. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2014;134:314-22
87. Wouters EF, Bredenbroker D, Teichmann P, et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:E1720-5
88. Lipari M, Kale-Pradhan PB. Vulnerable COPD patients with comorbidities: the role of roflumilast. Ther Clin Risk Manag 2014;10:969-76
89. O'Donnell DE, Bredenbröker D, Brose M, et al. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J 2012;39:1104-12
90. Rennard SI, Sun SX, Tourkodimitris S, et al. Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials. Int J Chron Obstruct Pulmon Dis 2014;9:657-73
91. Pan L, Guo YZ, Zhang B, et al. Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis. J Thorac Dis 2013;5:422-9
92. Vestbo J, Tan L, Atkinson G, et al. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 2009;33:1039-44
93. Wittmann M, Helliwell PS. Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases. Dermatol Ther (Heidelb) 2013;3:1-15
94. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates antiinflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159:842-55
95. Heckman PR, Wouters C, Prickaerts J. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview. Curr Pharm Des 2015;21:317-31
96. García-Barroso C, Ugarte A, Martinez M, et al. Phosphodiesterase inhibition in cognitive decline. J Alzheimers Dis 2014;42 Suppl 4:S561-73
97. García-Osta A, Cuadrado-Tejedor M, García-Barroso C, et al. Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease. ACS Chem Neurosci 2012;3:832-44
98. Jabaris SGSL, Sumathy H, Kumar RS, et al. Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats. Eur J Pharmacol 2015;746:138-47
99. Martinez A, Gil C. cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Expert Opin Ther Pat 2014;24:1311-21